Congenital cranial dysinnervation disorders (CCDDs) comprise a heterogeneous spectrum of diseases characterized by congenital, non-progressive impairment of eye, eyelid and/or facial movements including Mö bius syndrome, Duane retraction syndrome, congenital ptosis, and congenital fibrosis of the extraocular muscles. Over the last 20 years, several CCDDs have been identified as neurodevelopmental disorders that are caused by mutations of genes involved in brain and cranial nerve development, e.g. KIF21A and TUBB3 that each plays a pivotal role for microtubule function. In a five-generation pedigree, we identified a heterozygous mutation of TUBB6, a gene encoding a class V tubulin which has not been linked to a human hereditary disease so far. The missense mutation (p.Phe394Ser) affects an amino acid residue highly conserved in evolution, and co-segregates with a phenotype characterized by congenital non-progressive bilateral facial palsy and congenital velopharyngeal dysfunction presenting with varying degrees of hypomimia, rhinophonia, impaired gag reflex and bilateral ptosis. Expression of the mutated protein in yeast led to an impaired viability compared to wildtype cells when exposed to the microtubule-poison benomyl. Our findings enlarge the spectrum of tubulinopathies and emphasize that mutations of TUBB6 should be considered in patients with congenital non-progressive facial palsy. Further studies are needed to verify whether this phenotype is indeed part of the CCDD spectrum.
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Introduction
In 2002, the term 'congenital cranial dysinnervation disorders' (CCDD) was coined for a heterogeneous group of disorders that are defined by congenital, non-progressive, developmental anomalies of eye movements, eyelid and/or facial movements (1) . The broad spectrum of CCDDs embraces Mö bius syndrome (MIM 157900), Duane retraction syndrome (DURS, PS126800), hereditary congenital ptosis (PTOS1, MIM 178300; PTOS 2, MIM 300245), hereditary congenital facial paresis (HCFP, PS601471), and congenital fibrosis of the extraocular muscles (CFEOM, PS135700) (2) . While the genetic background of many of these disorders has been unraveled within the last 15 years, the full range of genes involved in the pathogenesis of CCDD remains elusive. Many of the hitherto identified genes play a crucial role during brain development, e.g. CHN1 (DURS2) (3), ROBO3 (the CCDD-related disorder horizontal gaze palsy with progressive scoliosis) (4), PHOX2A (CFEOM2) (5, 6) and KIF21A (CFEOM1) (7) (8) (9) . The proteins that are encoded by these genes are predominantly involved in axon guidance, axonal outgrowth or the generation and survival of brainstem motoneurons.
Among these genes, those encoding-specific tubulins play an important role in the pathogenesis of these neurodevelopmental disorders, e.g. in CFEOM (10, 11) . The concept according to which CFEOMs represent primary myopathic disorders has been proven wrong. Instead, mutations of specific tubulin isotypes have been identified in CFEOM patients (12) . According to these findings, mutations of tubulins can cause agenesis/hypoplasia of cranial nerve nuclei with subsequent dysinnervation and fibrosis of the extraocular muscles (13) .
Tubulins are heterodimers that consist of two chains (alpha and beta), which are each encoded by distinct genes. There are at least seven subtypes (classes) of tubulin beta chains that differ in their expression pattern and presumably in their intracellular function (14) . Tubulins form microtubules, which are essential for the cytoskeleton and thereby for cell division, differentiation and migration as well as intracellular trafficking (15) . Mutations of tubulins can lead to a broad spectrum of disorders, called 'tubulinopathies', including impaired genesis of cranial nerve nuclei and congenital cortical malformations (12) . While some of the tubulin classes have already been identified to cause specific disorders (16) , it remains unclear whether mutations of tubulin class V -encoded by TUBB6 (http://www.genenames.org/cgi-bin/gene_ symbol_report?hgnc_id=HGNC:20776) located on chromosome 18p11.21-are also potentially disease causing. We now provide evidence that a heterozygous missense mutation of TUBB6 leads to congenital bilateral non-progressive facial palsy and velopharyngeal dysfunction. Further studies are needed to verify whether congenital dysinnervation is the underlying mechanism, in order to potentially classify this phenotype as a novel CCDD subtype.
Results

Patients
The index patient was born to non-consanguineous parents after an uneventful pregnancy at 39 þ 4 weeks of gestation: birth weight 2920 g (P18); length 51 cm (P66), occipital frontal circumference (OFC) 34.0 cm (P37); APGAR score 10/10. She had several apnea attacks at four to five weeks of age, but subsequently experienced an uneventful infancy with an age-matched psychomotor development during infancy. However, bilateral ptosis and bilateral congenital facial palsy were observed. Given that similar symptoms had been repeatedly described within the paternal family, the family did not initiate any diagnostic approaches regarding the index patient within her first three years of life.
At 4 years of age, the girl was for the first time presented to our pediatric neurology department with mild congenital bilateral non-progressive facial palsy with severe bilateral ptosis and reduced motility of the levator palpebrae muscles with compensatory chin up posture [Figs 1 and 2 (patient VI: 9), Table 1 ]. She additionally showed velopharyngeal dysfunction with a wide uvula, absent gag reflex, and severe rhinophonia aperta. The ophthalmologic examination revealed subtle impairment of ocular elevation during following movements, potentially feigned by ptosis with a strong head posture. This mild impairment disappeared with increasing age of the patient. Bell's phenomenon, i.e. elevation of the eyes with intended lid closure, was intact, yet the power of the orbicularis oculi muscles was reduced (Fig. 2) . On physical examination, tongue motility was not reduced, neither was there tongue atrophy. Auditory and olfactory senses were not impaired. Other co-morbidities (e.g. skeletal anomalies) were not observed. Her cognitive development was above average (IQ ¼ 113 at age 4 years and 11 months; cognitive assessment revealed score for ages 3-5 ['KFT-K'¼ cognitive ability test, nursery school level]). Her psychomotor development was above age-matched average regarding social skills, while being age-appropriate regarding fine and gross motor skills. Speech and language assessment revealed a phonetic disorder, i.e. the articulation was impaired and characterized by a blurred, imprecise pronunciation, with rhinophonia and rhinolalia aperta, yet with age appropriate lexicon and grammar, normal suprasegmental use of speech cues like intonation, and speech fluency. At 5.5 years of age her body measurements were at the lower range: body weight 15 kg (P1), body length 107 cm (P6), OFC 48.5 cm (P2). In sum, based on the key clinical findings (i.e. congenital bilateral non-progressive facial palsy with severe bilateral ptosis, and velopharyngeal dysfunction), a congenital cranial dysinnervation disorder including hereditary congenital facial paresis was the primary differential diagnosis.
The patient's mother and the maternal family were unaffected. Yet, the patient's father was affected by similar symptoms, however in a milder form: he had had a hypomotile upper lip which had normalized until adulthood, however he was still showing mild rhinophonia aperta and a reduced gag reflex (Fig. 1, Table 1 , patient V: 12). As a child, he had suffered of regurgitating liquids through the nose when drinking. The index patient's younger sister (VI: 10) and at least 15 further members of the paternal family (Figs 1-3) showed varying degrees of rhinophonia aperta, reduced gag reflex, impaired facial movement and ptosis ( Table 1 ). The phenotype was non-progressive, and several affected individuals claimed improved symptoms as a result of speech therapy. None of the affected individuals showed the limitation of ocular abduction or limb abnormalities as described for Mö bius syndrome (17, 18) . Taken together, congenital, non-progressive bilateral facial palsy, velopharyngeal dysfunction and congenital ptosis were the predominant clinical findings of affected individuals within this family, albeit with a pronounced intra-familiar variability.
Three of the patients had previously had cranial MRIs for reasons other than the above-mentioned clinical findings (VI: 10 for dystrophy; V: 12 and IV: 4 for migraine). None of the MRIs revealed any obvious structural pathology (data not shown).
As a genetic origin was most probable, we initially performed karyotyping including FISH analysis in the index patient to exclude a microdeletion 22q11.2 as the cause of the rhinophonia, with normal results. 
Genetic analysis
Genome-wide SNP-based linkage analysis yielded a single peak with a maximal LOD score of 3.61 for a 6.4 Mb interval on the short arm of chromosome 18 between SNP_A-1515398 (rs1470248, position: 8514027) and SNP_A-1519122 (rs786000, position: 14905817) (Fig. 4A) . The linked chromosomal interval contains 57 RefSeq genes, none of which was known to be a disease gene associated with a phenotype remotely resembling CCDD. Whole-exome sequencing was performed in 2 affected individuals (IV: 4 and VI: 10). Filtering of data -as specified in Materials and Methods-limited the number of shared DNA variants in coding genes to 17 very rare variants. Of these only one, namely c.1181 T > C in TUBB6 (NM_032525), localized to the linked region on chromosome 18. The heterozygous c.1181 T > C transition was confirmed by Sanger sequencing not only in the index patient (Fig. 4B ), but in all affected family members whether severely or mildly affected (except for III: 6 who was not available, and for VI: 3 and VI: 4 whose parents did not consent to genetic testing in view of their obvious phenotype). The mutation was excluded in the healthy family members III: 5, IV: 1, V: 8. This result was consistent with the linkage data; i.e. the mutation cosegregated with the phenotype. The c.1181 T > C mutation is predicted to result in the missense mutation p.Phe394Ser affecting an amino acid residue that is highly conserved in evolution, both in orthologues and in paralogues (eight A-tubulin genes, and among all other eight b-tubulin isotypes) ( Fig. 5A and B) . This variant was predicted to be damaging by Polyphen2 (score 0.914) and disease causing by MutationTaster (score >0.99), the CADD score is 27.6 also compatible with a disease causing role. The p.Phe394 residue of TUBB6 corresponds to position p.Phe404 of the alpha tubulin in the refined structure of ab-tubulin at 3.5 Å resolution (database entry 1JFF.pdb) which is a taxol-bound alpha-beta tubulin dimer and the best fitting available crystal structure of tubulin (https:// (Fig. 1) showed bilateral facial palsy. All family members depicted in (A) and (B) are affected except for the healthy individual V: 8. This key clinical finding was already visible during early childhood (IV: 4; VI: 3, VI: 4). Severely affected individuals were unable to whistle or blow (IV: 4; V: 7), while moderately affected patients were able to whistle but not to completely retract their upper lip (IV: 2). Bilateral ptosis was occasionally seen (e.g. V: 7). Additional findings were rhinophonia aperta and a reduced gag reflex (see Table 1 ).
www.rcsb.org/; date last accessed 20 July 2017). The residue p.Phe404 is located in the highly conserved alpha helix H11' between the H11 and H12 loop of the C-terminal domain and thus positioned at an interface for longitudinal inter-dimer contacts that are involved in dynamical dis/assembly of microtubules (Supplementary Material, Fig. S1 ). The adjacent externalized antiparallel helices H11 and H12 mediate interaction with microtubule-based motors (dyneins and kinesins) and with microtubule associated proteins (19) . The mutation was neither found in ExAC nor in 1000 G as of 21 May 2017. None of the 16 unrelated sporadic patients with suspected CCDD carried a potentially pathogenic TUBB6 variant.
Moreover, a mutation of exactly the corresponding amino acid residue in the paralogue gene TUBB4A has been reported in hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC, OMIM 612438) (20) , and several heterozygous missense mutations of adjacent residues have been described in other paralogue tubulins (TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4B or TUBB8) (Fig. 5B) .
Functional analysis in a yeast model
To investigate the functional relevance of the identified TUBB6 variant we took advantage of the model system S. cerevisiae. Compared to human, the yeast S. cerevisiae has only one gene coding for beta-tubulin, the Tub2 gene. The resulting protein, Tub2p, has an identity of $75% to the human TUBB6 protein including the mutated residue. We were thus able to introduce the identified p.Phe394Ser missense mutation into yeast. We inserted the Tub2p F394S variant into one allele of a heterozygous S. cerevisiae strain at the endogenous Tub2 location, resulting in an expression from its native promotor and regulatory elements. Growth tests with yeast expressing Tub2p F394S in a heterozygous state showed a significantly higher sensitivity in the presence of the microtubule destabilizing drug benomyl as compared to wildtype yeast cells (Fig.  6A and B) . This indicates disturbed microtubules and further supports the pathogenic role of the identified p.Phe394Ser mutation in humans. 
Discussion
We here provide evidence that a mutation of TUBB6, a gene encoding class V tubulin, is associated with congenital, non-progressive bilateral facial palsy, velopharyngeal dysfunction with varying degrees of rhinophonia aperta, bilateral ptosis and reduced gag reflex. Eighteen members of a five-generation pedigree were affected by these core clinical findings. None of the affected individuals showed cognitive impairment. The cranial MRIs that were conducted on three affected patients were considered normal. Taken together, this is the first report identifying TUBB6 as disease causing gene, suggesting that a TUBB6 mutation may lead to a CCDD. However, further studies are needed to prove that, indeed, congenital dysinnervation is the underlying mechanism.
As congenital facial palsy was the core finding, we also included Mö bius syndrome into our initial differential diagnosis. However, the clinical picture of our patients differed significantly from Mö bius syndrome. The minimal diagnostic criteria for Mö bius syndrome are 'congenital, uni-or bilateral, nonprogressive facial weakness and limited abduction of the eye(s)' while vertical gaze is preserved (17, 21) . While all of our patients showed congenital bilateral, non-progressive facial palsy of varying degrees, none showed signs of limited abduction, which is in contrast to the definition of Mö bius syndrome. In addition, comorbidities that are occasionally seen in patients with Mö bius syndrome -e.g. developmental delay, generalized muscular hypotonia, behavioral impairment, craniofacial dysmorphism, limb and/or skeletal abnormalities, peripheral neuropathy and/or Poland anomaly (¼ pectoral hypoplasia) (17) -were neither present in our patients.
We speculate that the TUBB6 mutation caused the phenotype by affecting the development of the cranial nerves (and/or their nuclei) VII (facial nerve), IX (glossopharyngeal nerve) and potentially X (vagus nerve). The Eurexpress transcriptome database for mouse embryo (www.eurexpress.org; date last accessed 20 July 2017) specifically lists the following sites of strong expression for TUBB6 at day 14.5 pc: ganglia of cranial nerves V, VII, VIII, IX, X and spinal dorsal root ganglia. Moderate expression is found in the telencephalon as part of the forebrain, in the midbrain, and in the medulla oblongata and metencephalon as part of the hindbrain. According to this database, TUBB6 is not expressed in any type of muscle tissue, thus strengthening our hypothesis that TUBB6 mutations lead to a CCDD rather than to a primary myopathy. However, further studies are needed to prove this hypothesis. Although the cranial MRIs in three affected individuals were evaluated as unremarkable, this does not rule out that this particular TUBB6 mutation might alter human brain development. More specific imaging of the brain stem and the cranial nerve nuclei would have been desirable but none of the patients was available for such additional investigation. Given the extensive evidence linking mutations in tubulin genes with neurodevelopmental disorders -e.g. in CFEOM (22, 23) , hereditary dystonia (24) and malformations of cortical development (22, (25) (26) (27) (28) (29) (30) (31) (32) (33) -it is tempting to suggest that this TUBB6 mutation should be added to the spectrum of 'tubulinopathies' (12) .
As our study does not allow any conclusion on the detailed pathophysiological consequences of this TUBB6 mutation, we can only speculate how the mutation may cause the patients' phenotype. We show that this TUBB6 mutation, when expressed in yeast, leads to an increased sensitivity towards benomyl indicating reduced microtubule stability as compared to wildtype cells. This may suggest at least two potential mechanisms. A first possible mechanism could be that the mutation led to an impairment of axon guidance or outgrowth. In mice, the mutation of a specific tubulin subtype (TUBA1A) leads to decreased stability of microtubules during motor axon extension, disrupted post-synaptic function and subsequent dysinnervation of the according muscles (34) . Also, the mutation of another tubulin subtype (TUBB3) can affect the interaction of microtubules with kinesin thereby altering axonal growth (35) . A second potential mechanism could be that the mutation induced hypo-/agenesis of affected cranial nerve nuclei (facial, glossopharyngeal and vagus nerve), as previously reported in patients with Mö bius syndrome (36) . This could have been mediated by a cascade of altered cytoskeleton stability, impaired cell division (37) and proliferation during brain development. While the cranial MRIs of three affected individuals -all being normal -do not support this hypothesis, several lines of evidence are in line with this mechanism: first, Bhattacharya et al. have shown that over-expression of class V tubulins can lead to impaired cell division through an increased microtubule shortening rate and microtubule detachment from centrosomes (38) (39) (40) . Also, class V tubulins are involved in microtubule detachment from the centrosome within the organ of Corti, where they are expressed in a key stage of development (41) . Further, a human singlenucleotide polymorphism near TUBB6 leads to its increased expression and is associated with impaired microtubule stability (42, 43) . Finally, the class V tubulin expression fits nicely to the proposed mechanism: in mice brains, TUBB6 expression is predominant in neurons during early developmental stages, while declining during brain maturation (44) . More specifically, a Tub2pWT and WT/Tub2pF394S cells were washed twice and used for inoculation of 96-well plates containing YPD media with benomyl concentrations ranging from 0 to 40 mg/ml. Plates were incubated at 30 C for 24 h, the cells were resuspended and the OD 600 was recorded using a microplate reader. Growth is expressed as percentage of control with no benomyl added. Every data point is the average of 20 replicates achieved in three different experiments. ***P < 0.005.
genome-wide transcriptome atlas displays its expression in the hindbrain of mice during brain development (45) . Alternatively, the class V tubulin mutation could have indirectly affected brain development via an alteration of class III tubulin function, a tubulin isotype that is linked to CCDDs (23, 31) . This hypothesis is supported by a study which showed that class V tubulin is expressed in a complementary pattern to class III tubulin (46) . Further studies are needed to elucidate the underlying cellular mechanism in our patients and to determine whether the mutation acts through haploinsufficiency or as a dominantnegative mutation. As others (19) have pointed out, the mutation load in tubulin genes (missense rather than truncating mutations) is suggestive of a dominant-negative action of the mutated tubulin isotype on tubulin heterodimerization and microtubule assembly. In our case, the exchange of the hydrophobic amino acid Phe against the hydrophilic amino acid Ser at the interface of beta-alpha tubulin interaction may indeed affect the dynamic instability of the microtubules as suggested by the functional results in the yeast model.
In summary, our study identifies TUBB6 as disease causing gene in humans and possibly expands the spectrum of genetically explained CCDDs. The pathogenic relevance of TUBB6 thus deserves further attention for neurodevelopmental disorders such as in patients with congenital bilateral facial palsy.
Materials and Methods
Patients
The five-generation family comprising at least 40 members is of German descent (Fig. 1) . DNA was obtained from 9 affected family members (IV: 2, IV: 3, IV: 4, IV: 5, V: 7, V: 9, V: 12, VI: 9 and VI: 10), 4 unaffected family members (IV: 1, V: 6, V: 8, V: 11) and additionally from 2 unrelated mothers of affected children (III: 5, V: 13). An ophthalmologic examination was performed in 4 family members (IV: 5, V: 12, VI: 9, VI: 10). Cranial MRI was performed in 3 patients (IV: 4, V: 12 and VI: 10).
In addition, samples from 16 unrelated patients were selected from a cohort of patients with presumed congenital cranial dysinnervation disorders, comprising 2 patients with Möbius syndrome and 14 patients with uni-or bilateral ptosis (two of them with Marcus Gunn synkinesia) and uni-or bilateral elevation deficiency of the eyes or combinations of ptosis and elevation deficiency.
A search in Gene Matcher (https://genematcher.org) for TUBB6-related calls did not produce any hit as of 21 May 2017. Searching the Decipher developmental disorder database (https://decipher.sanger.ac.uk/) did not yield any individual with isolated TUBB6 duplication or deletion but only 62 individuals with multigene encompassing deletions/duplications including TUBB6 as of 21 May 2017.
Written informed consent for the study and publication was obtained from all patients and/or legal representatives. All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Genetic analysis
Genomic DNA was isolated from peripheral blood lymphocytes by standard procedures. Genome-wide linkage analysis was performed using the Affymetrix 10k SNP-array on 15 probands from 4 generations (9 affected individuals and 6 unaffected individuals). Data were checked using the program Graphical Representation of Relationships (GRR) (47) . Linkage analysis was performed assuming autosomal dominant inheritance, full penetrance, and a disease gene frequency of 0.0001. Multipoint LOD scores were calculated and haplotypes were reconstructed with ALLEGRO (48) . All data handling was done using the graphical user interface ALOHOMORA (49) .
For Sanger sequencing purified PCR products were sequenced by BigDye terminator ready reaction kit v.1.1 (Life Technologies), using a 3500 Genetic Analyzer (Applied Biosystems). For primers used to sequence TUBB6 exons, please refer to Supplementary Material, Table S1 . Resulting sequences were evaluated with the Sequence Pilot TM software (JSI Medical Systems GmbH, Germany).
For whole exome sequencing the Agilent Sureselect enrichment kit V6 was used (50) producing 9 Gb of sequence data that resulted in 85% of target region covered at least 30x. Filtering and variant calling were carried out using the Cologne Center for Genomics (CCG) VARBANK database and analysis tool (https:// varbank.ccg.uni-koeln.de; date last accessed 20 July 2017) as described previously (51). Filters were adjusted for high-quality (minimal read coverage >15Â; phred-scaled quality >25), rare (minor allele frequency 0.01) variants based on dbSNP134, the 1000 Genomes database build 20110521, the public Exome Variant Server, US National Heart, Lung and Blood Institute, build ESP5400 and an in-house database of 511 epilepsy patients.
The following genetic databases were used: National Center Missense variants were analysed in silico using MutationTaster (http://www.mutationtaster.org/) and PolyPhen-2 (polymorphism phenotyping v2, http://genetics.bwh.harvard.edu/pph2/) (52) . Potential splice sites variants were predicted with the following tools (MaxEntScan, HSF, MutationTaster, SIFT, PolyPhen-2) via AlamutVisual (Alamut Visual version 2.6; Interactive Biosoftware, Rouen, France), all accessed in July 2016.
For 3 D molecular modelling the TUBB6 sequence was blasted against the Protein Data Bank (https://www.rcsb.org/; date last accessed 20 July 2017) and the hit with highest homology and best crystal resolution, 1JFF an ab-tubulin dimer to 3.5 Å resolution, was chosen (53) . The position of the p.Phe404 that corresponds to p.Phe394 in TUBB6 was visualized in a ribbon diagram representation (above) and a surface rendering (below) using the NGL viewer.
Plasmids
The plasmid pGMI carrying the Tub2 WT sequence (54) was kindly provided by Mohan Gupta. pGMI-F394S was constructed by PCR-amplification of two fragments (Tub2pF1a-Tub2pmutR and Tub2pmuF-Tub2pR2) from vector-DNA, followed by recombinant-PCR with Tub2pF1a/Tub2pR2 using the PCRproducts of the first PCR as a template. The obtained 1 kb fragment was subcloned into pGMI using BsiWI/PshAI restriction sites. The mutation was verified by Sanger sequencing.
Primer: Tub2pF1a: 5'-TGCACCAATTGGTAGAACACTC-3' Tub2pmutR: 5'-CCAGTGCAAGgAAGCTTTTC-3' Tub2pmutF: 5'-GAAAAGCTTcCTTGCACTGG-3' Tub2pR2: 5'-CAATAGCTCGGAAGGTTAAAGG-3'
Yeast strains, media and culture conditions
Yeast strain BY4743 (MATa/MATa his3D 0/his3D 0; leu2D/leu2D 0; met15D 0/MET15; LYS2/lys2D 0; ura3D 0/ura3D 0) was obtained from Euroscarf. Mutation strains were constructed by transformation of BY4743 with the gel-purified SacI/SphI fragment of pGMI carrying wild-type Tub2p or Tub2p_F394S respectively, using the lithium acetate method of Ito et al. (55) and selecting for colonies on plates lacking uracil. Successful transformation was confirmed by PCR and sequencing of the Tub2 gene. Cells were grown in YPD media (1% yeast extract, 2% bactopeptone and 2% glucose) or in synthetic complete (SC) media (0.67% yeast nitrogen base without amino acids, 2% glucose and appropriate supplements as needed). For maintenance of the mutations cells were grown in SC media lacking uracil (SC-URA). For plate tests, cells were grown overnight in SC-URA, fivefold serial dilutions were made starting with 107 cells/ml and 3.5 ml aliquots were spotted onto the indicated plates and incubated at 30 C for 2-4 days. For growth curves cells were grown overnight in SC-URA, diluted to an OD600 of 0, 2 and grown for 3.5 h. Then they were washed twice with sterile water and diluted to an OD600 of 2.5. 96-well plates containing 200 ml YPD with the indicated benomyl-concentrations and were inoculated with 3.5 ml of the washed cultures. The plates were incubated for 24 h/48 h at 30 C and the OD600 was recorded using a microplate reader (EPOCH).
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